Genovate Biotechnology Co., Ltd.,   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Taipei Taiwan (1995)
Status: No NME R&D (1995)

Organization Overview

First Clinical Trial
2003
NCT00244231
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Genovate Biotechnology Co., Ltd.,

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Body Weight (Phase 4)

Dyslipidemias (Phase 4)

Glaucoma (Phase 4)

Hyperglycemia (Phase 4)

Hyperlipidemias (Phase 3)

Hyperlipoproteinemias (Phase 3)

Hyperprolactinemia (Phase 4)

Intermittent Claudication (Phase 1)

Lupus Nephritis (Phase 2)

Nephritis (Phase 2)

Weight Gain (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial APIs: 12